Related Experiment Video

Updated: Jun 2, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from

Lingling Feng1, Li Zhou, Yao Sun

  • 1Key Laboratory of Pesticide & Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, PR China. fll708@mail.ccnu.edu.cn

Bioorganic & Medicinal Chemistry
|May 10, 2011
PubMed

Insights

Annonaceous acetogenins (ACGs) show potent inhibition against Streptococcus pneumoniae 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), offering a new avenue for developing antibacterial drugs against this pathogen.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Microbiology

Background:

  • 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a key enzyme in bacterial pathways.
  • Streptococcus pneumoniae infections pose a significant public health challenge.
  • Effective inhibitors for bacterial class II HMGR are currently lacking.

Purpose of the Study:

  • To investigate the inhibitory potential of annonaceous acetogenins (ACGs) against Streptococcus pneumoniae HMGR.
  • To explore ACGs as novel drug candidates for treating S. pneumoniae infections.

Main Methods:

  • Enzyme inhibition assays were performed to quantify the activity of ACGs.
  • In silico methods, including 3D modeling and docking simulations, were employed.
  • Comparison of ACG inhibition with the statin drug lovastatin.

Main Results:

  • Four ACGs demonstrated significant inhibitory activity against S. pneumoniae HMGR.
  • The K(i) values for ACGs ranged from 6.45–20.49 μM, outperforming lovastatin (K(i)=116.25 μM).
  • Molecular modeling suggested a novel binding mode for ACGs within the enzyme's active site.

Conclusions:

  • Annonaceous acetogenins are promising inhibitors of S. pneumoniae class II HMGR.
  • The identified binding mode provides a basis for designing more potent antibacterial agents.
  • ACG-based therapeutics could offer a new strategy against invasive pneumococcal diseases.

More Related Videos

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.